OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
2
Results
Show all
Save search
Copy query
Show results for
Unknown
(2)
Publication Date
Release Date
2021
(2)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Not available
S-EPMC7801303
|
biostudies-literature
Cite
Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
Not available
S-SCDT-EMM-2020-13742
|
biostudies-other
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
